SARS CoV‐2 related microvascular damage and symptoms during and after COVID‐19: Consequences of capillary transit‐time changes, tissue hypoxia and …
L Østergaard - Physiological reports, 2021 - Wiley Online Library
Abstract Corona virus disease 2019 (COVID‐19) causes symptoms from multiple organs
after infection by severe acute respiratory syndrome corona virus 2 (SARS CoV‐2). They …
after infection by severe acute respiratory syndrome corona virus 2 (SARS CoV‐2). They …
[HTML][HTML] Interrelationship between COVID-19 and coagulopathy: pathophysiological and clinical evidence
B Ragnoli, B Da Re, A Galantino, S Kette… - International Journal of …, 2023 - mdpi.com
Since the first description of COVID-19 infection, among clinical manifestations of the
disease, including fever, dyspnea, cough, and fatigue, it was observed a high incidence of …
disease, including fever, dyspnea, cough, and fatigue, it was observed a high incidence of …
Antiplatelet therapy and outcome in COVID-19: the health outcome predictive evaluation registry
F Santoro, IJ Nuñez-Gil, E Vitale, MC Viana-Llamas… - Heart, 2022 - heart.bmj.com
Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies
showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the …
showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the …
Decreased in‐hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID‐19
M Haji Aghajani, O Moradi, H Amini… - Journal of Medical …, 2021 - Wiley Online Library
Hypercoagulability and thrombosis caused by coronavirus disease 2019 (COVID‐19) are
related to the higher mortality rate. Because of limited data on the antiplatelet effect, we …
related to the higher mortality rate. Because of limited data on the antiplatelet effect, we …
[HTML][HTML] Koagulopati pada Coronavirus Disease-2019 (COVID-19): Tinjauan pustaka
HA Willim, AT Hardigaloeh, AI Supit… - Intisari Sains …, 2020 - isainsmedis.id
Background: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 has spread …
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 has spread …
Association between cardiovascular disease, cardiovascular drug therapy, and in-hospital outcomes in patients with COVID-19: data from a large single-center …
M Terlecki, W Wojciechowska… - Kardiologia Polska …, 2021 - journals.viamedica.pl
Background: The coronavirus disease 19 (COVID-19) recently became one of the leading
causes of death worldwide, similar to cardiovascular disease (CVD). Coexisting CVD may …
causes of death worldwide, similar to cardiovascular disease (CVD). Coexisting CVD may …
[HTML][HTML] Efficacy of ceftazidime and cefepime in the management of COVID-19 patients: single center report from Egypt
The purpose of this study was to explore the value of using cefepime and ceftazidime in
treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed …
treating patients with COVID-19. A total of 370 (162 males) patients, with RT-PCR-confirmed …
[HTML][HTML] A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.
Y Mohamed, YA El-Maradny, AK Saleh… - Biomedicine & …, 2022 - Elsevier
The healthy immune system eliminates pathogens and maintains tissue homeostasis
through extraordinarily complex networks with feedback systems while avoiding potentially …
through extraordinarily complex networks with feedback systems while avoiding potentially …
Flavonoids as a therapeutical option for the treatment of thrombotic complications associated with COVID‐19
JP Quintal Martínez… - Phytotherapy …, 2023 - Wiley Online Library
The SARS‐CoV‐2 outbreak has been one of the largest public health crises globally, while
thrombotic complications have emerged as an important factor contributing to mortality …
thrombotic complications have emerged as an important factor contributing to mortality …
Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study
A Sisinni, L Rossi, A Battista, E Poletti, F Battista… - International Journal of …, 2021 - Elsevier
Background Patients with coronavirus disease 2019 (COVID-19) exhibit high thrombotic risk.
The evidence on a potential independent prognostic role of antiplatelet treatment in those …
The evidence on a potential independent prognostic role of antiplatelet treatment in those …